Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T cell infiltration

PURPOSE: A phase I study was conducted to determine safety, clinical efficacy, and anti-tumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral (IT) administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lee, Jay M., Lee, Mi-Heon, Garon, Edward B., Goldman, Jonathan W., Salehi-Rad, Ramin, Baratelli, Felicita E., Schaue, Dörthe, Wang, Gerald, Rosen, Fran, Yanagawa, Jane, Walser, Tonya C., Lin, Ying, Park, Stacy J., Adams, Sharon, Marincola, Francesco M., Tumeh, Paul C., Abtin, Fereidoun, Suh, Robert, Reckamp, Karen L., Lee, Gina, Wallace, William D., Lee, Sarah, Zeng, Gang, Elashoff, David A., Sharma, Sherven, Dubinett, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599263/
https://ncbi.nlm.nih.gov/pubmed/28468947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados